Business Context and Reporting Period
Cytosorbents Corp, a Delaware corporation, filed this Form 8-K on May 22, 2018, reporting events occurring on May 22 and May 23, 2018. The filing addresses a specific transaction involving the issuance of common stock to satisfy a contractual obligation.
Key Financial Metrics
This filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a non-cash equity transaction.
Material Changes
The Company issued an aggregate of 68,791 shares of common stock (par value $0.001 per share) to Western Alliance Bancorporation. This issuance was made in full satisfaction of the Company's obligations under a Success Fee Letter dated June 30, 2016, with Western Alliance Bank. The shares were issued on May 23, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the specific event of the stock issuance. The transaction was facilitated through a prospectus supplement to the Company's existing Form S-3 registration statement.
Investor Verification Checklist
- Verify the total number of shares issued (68,791) and the date of issuance (May 23, 2018).
- Confirm the identity of the recipient (Western Alliance Bancorporation) and the nature of the obligation satisfied (Success Fee Letter dated June 30, 2016).
- Review the referenced Form S-3 Registration Statement (File No. 333-205806) for broader context on the Company's equity structure.
- Note that this filing does not contain updated financial statements or operational results.